PMID- 18502834
OWN - NLM
STAT- MEDLINE
DCOM- 20080916
LR  - 20220318
IS  - 1528-0020 (Electronic)
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 112
IP  - 4
DP  - 2008 Aug 15
TI  - Change in plasma tumor necrosis factor receptor 1 levels in the first week after 
      myeloablative allogeneic transplantation correlates with severity and incidence 
      of GVHD and survival.
PG  - 1539-42
LID - 10.1182/blood-2008-02-138867 [doi]
AB  - Acute graft-versus-host disease (GVHD) remains a significant cause of mortality 
      after hematopoietic cell transplantation (HCT). Tumor necrosis factor-alpha 
      (TNF-alpha) mediates GVHD by amplifying donor immune responses to host tissues 
      and by direct toxicity to target organs. We measured TNF receptor 1 (TNFR1) as a 
      surrogate marker for TNF-alpha in 438 recipients of myeloablative HCT before 
      transplantation and at day 7 after transplantation. Increases in TNFR1 levels 
      more than or equal to 2.5 baseline correlated with eventual development of GVHD 
      grade 2 to 4 (58% vs 32%, P < .001) and with treatment-related mortality (39% vs 
      17%, P < .001). In a multivariate analysis including age, degree of HLA match, 
      donor type, recipient and donor sex, disease, and status at HCT, the increase in 
      TNFR1 level at day 7 remained a significant predictor for outcome. Measurement of 
      TNFR1 levels early after transplantation provides independent information in 
      advance of important clinical outcomes, such as GVHD and death.
FAU - Choi, Sung W
AU  - Choi SW
AD  - Department of Pediatrics, Blood and Marrow Transplantation Program, University of 
      Michigan, Ann Arbor, MI 48109-5942, USA.
FAU - Kitko, Carrie L
AU  - Kitko CL
FAU - Braun, Thomas
AU  - Braun T
FAU - Paczesny, Sophie
AU  - Paczesny S
FAU - Yanik, Gregory
AU  - Yanik G
FAU - Mineishi, Shin
AU  - Mineishi S
FAU - Krijanovski, Oleg
AU  - Krijanovski O
FAU - Jones, Dawn
AU  - Jones D
FAU - Whitfield, Joel
AU  - Whitfield J
FAU - Cooke, Kenneth
AU  - Cooke K
FAU - Hutchinson, Raymond J
AU  - Hutchinson RJ
FAU - Ferrara, James L M
AU  - Ferrara JL
FAU - Levine, John E
AU  - Levine JE
LA  - eng
GR  - P01 CA039542/CA/NCI NIH HHS/United States
GR  - P30 CA046592/CA/NCI NIH HHS/United States
GR  - 2P01CA039542-18/CA/NCI NIH HHS/United States
GR  - 5P30CA046592/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20080523
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (Myeloablative Agonists)
RN  - 0 (Receptors, Tumor Necrosis Factor, Type I)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Child
MH  - Child, Preschool
MH  - Female
MH  - Graft vs Host Disease/*diagnosis
MH  - Hematopoietic Stem Cell Transplantation/*adverse effects/methods/mortality
MH  - Humans
MH  - Incidence
MH  - Infant
MH  - Infant, Newborn
MH  - Male
MH  - Middle Aged
MH  - Myeloablative Agonists/*therapeutic use
MH  - *Predictive Value of Tests
MH  - Prognosis
MH  - Receptors, Tumor Necrosis Factor, Type I/*blood
MH  - Survival Rate
MH  - Time Factors
MH  - Transplantation Conditioning/adverse effects/*methods
MH  - Transplantation, Homologous
MH  - Tumor Necrosis Factor-alpha/analysis
PMC - PMC2515125
EDAT- 2008/05/27 09:00
MHDA- 2008/09/17 09:00
PMCR- 2009/08/15
CRDT- 2008/05/27 09:00
PHST- 2008/05/27 09:00 [pubmed]
PHST- 2008/09/17 09:00 [medline]
PHST- 2008/05/27 09:00 [entrez]
PHST- 2009/08/15 00:00 [pmc-release]
AID - S0006-4971(20)49746-0 [pii]
AID - 2008/138867 [pii]
AID - 10.1182/blood-2008-02-138867 [doi]
PST - ppublish
SO  - Blood. 2008 Aug 15;112(4):1539-42. doi: 10.1182/blood-2008-02-138867. Epub 2008 
      May 23.